JPS58206757A - 血漿分画処理装置 - Google Patents
血漿分画処理装置Info
- Publication number
- JPS58206757A JPS58206757A JP57089770A JP8977082A JPS58206757A JP S58206757 A JPS58206757 A JP S58206757A JP 57089770 A JP57089770 A JP 57089770A JP 8977082 A JP8977082 A JP 8977082A JP S58206757 A JPS58206757 A JP S58206757A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- hollow fiber
- fiber membrane
- membrane
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title description 6
- 210000002966 serum Anatomy 0.000 title 1
- 239000012528 membrane Substances 0.000 claims description 89
- 239000012510 hollow fiber Substances 0.000 claims description 58
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 23
- 238000005194 fractionation Methods 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 9
- 210000002381 plasma Anatomy 0.000 description 70
- 210000004379 membrane Anatomy 0.000 description 46
- 238000000034 method Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000009027 Albumins Human genes 0.000 description 14
- 108010088751 Albumins Proteins 0.000 description 14
- 238000001914 filtration Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 10
- 238000011084 recovery Methods 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000011148 porous material Substances 0.000 description 5
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- -1 pseudo-macroglobulin Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010091326 Cryoglobulins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000012788 optical film Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57089770A JPS58206757A (ja) | 1982-05-28 | 1982-05-28 | 血漿分画処理装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57089770A JPS58206757A (ja) | 1982-05-28 | 1982-05-28 | 血漿分画処理装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58206757A true JPS58206757A (ja) | 1983-12-02 |
| JPH034230B2 JPH034230B2 (enExample) | 1991-01-22 |
Family
ID=13979917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57089770A Granted JPS58206757A (ja) | 1982-05-28 | 1982-05-28 | 血漿分画処理装置 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58206757A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018615A1 (ja) * | 2002-08-23 | 2004-03-04 | Asahi Medical Co., Ltd. | フィブリン含有組成物 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5332230B2 (ja) * | 2007-02-22 | 2013-11-06 | 東レ株式会社 | 血液処理カラム |
-
1982
- 1982-05-28 JP JP57089770A patent/JPS58206757A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018615A1 (ja) * | 2002-08-23 | 2004-03-04 | Asahi Medical Co., Ltd. | フィブリン含有組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH034230B2 (enExample) | 1991-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0120445B1 (de) | Verfahren und Vorrichtung zur selektiven extrakorporalen Abtrennung pathologischer und/oder toxischer Blutbestandteile | |
| CN100503020C (zh) | 血浆净化膜和血浆净化系统 | |
| US4212744A (en) | Haemodialyzer apparatus | |
| US4402940A (en) | Method for treating blood plasma employing a hollow fiber membrane | |
| DE3115608C2 (de) | Vorrichtung für die Adsorption von Blutproteinen | |
| EP1993631B1 (de) | Regenerierbares filter zur extrakorporalen behandlung partikelhaltiger flüssigkeiten und deren anwendung | |
| US20130035663A1 (en) | Anticoagulant-Free Dialysis Systems And Methods | |
| DE3225603A1 (de) | Kugelfoermige poroese granulate mit einer silanolgruppe auf ihrer oberflaeche sowie ihre verwendung zur herstellung einer blutreinigungsvorrichtung | |
| JPS6171063A (ja) | 血液中の高分子量種の選択的分離方法 | |
| JPH08295697A (ja) | 高濃度絹フィブロイン水溶液の製造方法 | |
| US20120031840A1 (en) | Method for reducing amyloid beta concentration in blood | |
| CN1330562A (zh) | 血液净化器 | |
| DE102008010691A1 (de) | Bioäquivalenzdialyse | |
| JPH06154306A (ja) | タンパク質含有体液の加工 | |
| JPS58206757A (ja) | 血漿分画処理装置 | |
| EP3185926B1 (de) | System zur entfernung von proinflammatorischen mediatoren sowie von granulozyten und monozyten aus blut | |
| EP0076320A1 (en) | Method and apparatus for treating blood and the like | |
| JPH0211263B2 (enExample) | ||
| JPS5894858A (ja) | 血漿を処理すべき装置 | |
| JPH03146067A (ja) | 血漿濾過方法 | |
| JPS58175565A (ja) | 血漿処理装置 | |
| JPS587258A (ja) | 血漿の浄化処理方法 | |
| JPH01254204A (ja) | ウイルス除去方法 | |
| Sun et al. | Blood Purification Membranes Used in Liquid–Liquid Environments | |
| JPS58173556A (ja) | 血液浄化装置 |